Marker Therapeutics, a clinical-stage immuno-oncology company, has entered into a manufacturing agreement with Cellipont Bioservices, a US-based cell therapy CDMO, to support the production of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy. The partnership will focus on cGMP manufacturing and
Mabion, a European biologics CDMO, has released the first batch of NovalGen’s NVG-222, a next-generation T-cell engager, ahead of its first-in-human clinical trials scheduled for the second half of 2025. The release marks a new phase in the strategic partnership
Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization (CDMO), has entered into a new 10-year commercial manufacturing and supply agreement with an existing client. The collaboration supports the continued development and future commercialisation of a novel ophthalmic
eXmoor Pharma, a UK-based CDMO with embedded consultancy capabilities, has announced a collaboration with France’s Signadori Bio to accelerate the development of gene-modified monocyte-derived macrophage therapies for solid tumours. The partnership will focus on advancing Signadori Bio’s lead candidate—developed at
Mabion, a biotech-focused CDMO, has launched a €500,000 contest aimed at accelerating the development of recombinant protein-based oncology treatments. The initiative was unveiled at BIO International Convention 2025 and will conclude at CPHI Worldwide in Frankfurt this October. The contest
Mycenax Biotech Inc. has entered into a strategic collaboration with Japan-based RIN Institute Inc. through a signed Letter of Intent (LOI), aiming to strengthen its contract manufacturing services in the antibody-drug conjugate (ADC) field. The agreement grants Mycenax and its ADC alliance,
Lotte Biologics, together with Axcelead Drug Discovery Partners, Inc. and Kanaph Therapeutics Inc., has signed a tripartite memorandum of understanding to jointly build an antibody-drug conjugate (ADC) toolbox platform. The initiative aims to enhance the development of next-generation ADC cancer therapies through shared
64x Bio, a biotechnology company focused on scalable manufacturing solutions for advanced therapies, has announced the launch of its AAV Apex Suite. The new product line is designed to address critical manufacturing challenges in gene therapy by increasing viral vector
Enzene, a specialist in continuous biologics manufacturing, has expanded its upcoming contract manufacturing site in Hopewell, near Princeton, New Jersey. The company announced an additional 26,000 square feet of space to the already planned 54,000 square feet. The enlarged site
Veranova has announced a strategic investment to establish bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts facility. The investment, which exceeds $50 million, aims to enhance the company’s offering for the development and production of antibody-drug conjugates (ADCs) and
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
